; (2) take into account the best available science; (3) consider different responses to differing levels of severity of a public health emergency, based on input from stakeholders, as well as from external sources, including the National Academies, academic sources, State, Tribal, territorial, and local governments, and the private sector; (4) evaluate the reliability and security of suppliers necessary to ensure the production, procurement, and distribution of critical nonpharmaceutical materials, including considering— (A) supplier diversity, country of origin, supply chain stability, and cybersecurity risk to distribution and to production facilities; (B) priority to domestic sources of supply; and (C) how to maximize the use of materials produced in the United States in accordance with section 3 of this Act